Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02643979 · ClinicalTrials.gov registry record · Phase 4
Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Terminated
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT02643979 is a Phase 4 study that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 22 participants.
The verdict
NCT02643979, a Phase 4 study, was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
Propofol is one of the most popular anesthetic drugs used for sedation during upper gastrointestinal endoscopies due to its quick onset and quick resolution of symptoms allowing patients to leave the hospital sooner. However, when administered it can also slow the breathing of patients and cause others to have upper airway obstruction (such as snoring) which can impede proper spontaneous breathing. Ketamine is an agent that is capable of providing both pain control and sedation while having either minimal effect on breathing or promoting spontaneous breathing. Combining Ketamine with Propofol has the potential to reduce the total amount of Propofol used resulting in a procedure being performed under the same level of sedation but without the downside of reduced spontaneous breathing. Patients who are obese (defined as body mass index greater than 35) tend to be even more susceptible to this effect of Propofol. The researchers are investigating whether the addition of Ketamine will indeed allow for this continued comfortable level of sedation while promoting continued spontaneous breathing in obese patients undergoing upper gastrointestinal endoscopies.
Interventions
- DRUG Saline
- DRUG Propofol
- DRUG Ketofol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-01-01 |
| Est. Completion | 2019-01-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02643979
The ClinicalTrials.gov registry entry for NCT02643979 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.
NCT02643979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02643979 about?
NCT02643979 is a clinical study titled "Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy". Propofol is one of the most popular anesthetic drugs used for sedation during upper gastrointestinal endoscopies due to its quick onset and quick resolution of symptoms allowing patients to leave the hospital sooner. However, when administered it can also slow the breathing of patients and cause oth...
What is the current status of trial NCT02643979?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2016-01-01. Estimated completion is 2019-01-05.
What interventions are being tested in trial NCT02643979?
The interventions under investigation include: Saline (DRUG), Propofol (DRUG), Ketofol (DRUG).
Who is sponsoring clinical trial NCT02643979?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.